Descripción de la empresa
Neumora Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of therapeutic interventions for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions within the United States market. The company functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, which implies a focus on early-stage drug discovery and clinical development rather than commercialized product sales. As of the latest reporting period, the company holds a market capitalization of $364.08M, while the specific figures for annual revenue and employee count are not disclosed in the available financial data. The absence of disclosed revenue and employee metrics suggests that the firm is likely in a phase of significant capital deployment for research and development, where market capitalization serves as the primary indicator of investor valuation rather than current operational scale or income generation.
Salud financiera
The reported revenue for the trailing twelve months is not available in the current dataset, but the net income stands at a loss of $-236,928,000, with an EBITDA of $-235,948,000. The substantial gap between the unavailable revenue figure and the significant net loss reveals a cost structure dominated by high research and development expenditures typical of clinical-stage biotechnology firms, where operating expenses far exceed any current sales revenue. Free cash flow is reported at $-115,712,376, indicating a continuous burn rate that limits immediate financial flexibility and necessitates external capital raising to sustain operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet achieved profitability from its sales or that revenue figures are insufficient to calculate meaningful margins in the absence of commercial product sales. On the balance sheet, the company holds $182.53M in cash against $55.01M in debt, resulting in a debt-to-equity ratio of 52.96, which suggests a highly leveraged position relative to equity but provides a substantial cash buffer for debt servicing. The current ratio stands at 5.87, a figure that indicates strong short-term liquidity and the ability to cover short-term obligations with current assets, although this liquidity is primarily driven by cash reserves rather than operational cash flow. Furthermore, the return on equity is -121.2% and the return on assets is -58.1%, metrics that reveal that management effectiveness in generating returns on shareholder capital and asset base is currently negative due to the company's developmental stage and lack of commercial earnings.
Evaluación de valoración
The trailing twelve-month P/E ratio is not available due to negative earnings, while the forward P/E is listed at -2.16, implying that the market anticipates continued negative earnings in the near term rather than immediate profitability. The price-to-book ratio is 3.36, indicating that the market values the company at a significant premium over its book value, reflecting the potential value of its intellectual property and pipeline despite current losses. Price-to-sales and EV/EBITDA metrics are unavailable or negative at -1.00 respectively, suggesting that traditional valuation multiples are not applicable for a pre-revenue company with negative earnings and that valuation relies heavily on market cap and cash position. The stock has traded between a 52-week low of $0.61 and a 52-week high of $3.65, placing the current trading range within a wide historical band that reflects the high volatility inherent in biotechnology equities. The beta value is 3.12, which signifies that the stock price is expected to fluctuate with significantly higher volatility than the broader market, exposing investors to substantial price swings during periods of market turbulence.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as not available, preventing a direct comparison of growth rates between sales and profitability, though the negative net income confirms that earnings are currently contracting or absent relative to any potential revenue generation. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that the company retains all available cash flow to reinvest into its clinical trials and drug development programs rather than distributing income to shareholders. This reinvestment strategy is standard for clinical-stage biopharmaceutical companies that prioritize growth capitalization over income distribution to their equity holders. The overall growth and income profile is characterized by a lack of current income generation and reliance on external financing to fund future growth potential in the neurodegenerative disease sector.